Expanding eligible patient populations for targeted therapies 

We are partnering with pharmaceutical companies to provide companion diagnostics for their existing or investigational targeted therapies.

CELsignia offers a new way to identify patients eligible for targeted therapies.

  • CELsignia tests diagnose dysregulated signaling cancer drivers that molecular based approaches cannot detect. Why? The nature of cell signaling is too dynamic and complex to be characterized by static analysis of fixed cells

These patients are likely drug responders.

  • The patients diagnosed with a dysregulated signaling pathway have a disease mechanism that directly corresponds to the matching targeted therapy’s mechanism of action.

CELsignia tests can help drug sponsors obtain new indications for their targeted therapies.

  • CELsignia tests provide pharmaceutical companies a new type of biomarker, dysregulated signaling activity, to identify additional patients eligible for their targeted therapies